Press release
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2022
Revenue of $1.16 billion for Q2 2022, up 3% from Q2 2021, and up 5% on a constant currency basisGAAP diluted loss per share of $(3.40) for Q2 2022, compared
About this update from Illumina, Inc.
[{"type":"text","content":"Revenue of $1.16 billion for Q2 2022, up 3% from Q2 2021, and up 5% on a constant currency basisGAAP diluted loss per share of $(3.40) for Q2 2022, compared to GAAP diluted earnings per share of $1.26 for Q2 2021; GAAP diluted loss per share for Q2 2022 includes $609 million in legal contingenciesNon-GAAP diluted earnings per share of $0.57 for Q2 2022, compared to non-GAAP diluted earnings per share of $1.87 for Q2 2021Expect full year revenue for fiscal year 2022 to grow 4% to 5% from fiscal year 2021, primarily reflecting the ongoing negative impact of foreign exchange rates, customer lab expansion delays, and macroeconomic-driven conservatism around immediate capital and inventory commitments, including in Greater ChinaExpect GAAP diluted loss per share of $(2.93) to $(2.78) for fiscal year 2022Expect non-GAAP diluted earnings per share of $2.75 to $2.90 for fiscal year 2022SAN DIEGO, Aug. 11, 2022 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) today announced its financial results for the second quarter of fiscal year 2022, which include consolidated financial results for GRAIL.\n\n \n \n \n \n \n \n\n \n\"Our second quarter results did not meet our expectations as challenges in a complex macroeconomic environment more than offset the growth we continue to see in sequencing runs on our platforms,\" said Francis deSouza, Chief Executive Officer. \"As we strategically navigate these dynamics, we continue to advance our innovation roadmap in support of our long-term growth trajectory. At our upcoming Illumina Genomics Forum and Investor Day events, we look forward to showcasing our breakthrough technologies that demonstrate the power and potential of genomics.\"\nSecond quarter consolidated results\nGAAP\nNon-GAAP (a)\nDollars in millions, except per share amounts\nQ2 2022 (b)\nQ2 2021\nQ2 2022 (b)\nQ2 2021\nRevenue\n$ 1,162\n$ 1,126\nGross margin\n66.0 %\n71.2 %\n69.4 %\n71.8 %\nResearch and development (\"R&D\") expense\n$ 327\n$ 202\n$ 327\n$ 202\nSelling, general and administrative (\"SG&A\") expense\n$ 410\n$ 413\n$ 339\n$ 269\nLegal contingencies\n$ 609\n$ —\n$ —\n$ —\nOperating (loss) profit\n$ (579)\n$ 187\n$ 141\n$ 338\nOperating margin\n(49.8) %\n16.6 %\n12.2 %\n30.0 %\nNet (loss) income\n$ (535)\n$ 185\n$ 91\n$ 276\nDiluted (loss) earnings per share\n$ (3.40)\n$ 1.26\n$ 0.57\n$ 1.87\n(a) See the tables included in \"...